[Vasodilator agents in pulmonary artery hypertension of systemic scleroderma].
An acute haemodynamic study was carried out prospectively in 6 patients fulfilling the diagnostic criteria of systemic sclerosis with pulmonary arterial hypertension. This study consisted of 7 baseline measurements and the effect of 6 drugs administered intravenously and known for their effects as vasodilators in the literature. These results were compared to those obtained on 44 patients suffering from pulmonary arterial hypertension previously studied at Hospital A.-Béclère. The prostacyclin (PGI2) possesses a very potent vasodilator effect, lowering the total pulmonary vascular resistance by 29% in patients suffering from scleroderma. As well as PGI2 phentolamine and hydralazine seemed to possess an acute vasodilator action which is certainly not negligible.
Phlippoteau
C
C
Service de Pneumo-Phtisiologie, Hôpital A.-Béclère, Clamart.
Brenot
F
F
Blétry
O
O
Simmonneau
G
G
Duroux
P
P
D000328:Adult; D000368:Aged; D001794:Blood Pressure / Q000187:drug effects; D002302:Cardiac Output / Q000187:drug effects; D011464:Epoprostenol / Q000627:therapeutic use; D005260:Female; D006801:Humans; D006830:Hydralazine / Q000627:therapeutic use; D006976:Hypertension, Pulmonary / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D008875:Middle Aged; D010646:Phentolamine / Q000627:therapeutic use; D011446:Prospective Studies; D011651:Pulmonary Artery / Q000502:physiology; D012595:Scleroderma, Systemic / Q000150:complications*; D014655:Vascular Resistance / Q000187:drug effects; D014665:Vasodilator Agents / Q000627:therapeutic use*
D014665:Vasodilator Agents; D006830:Hydralazine; D011464:Epoprostenol; D010646:Phentolamine
Etude des drogues vasodilatatrices dans l'hypertension artérielle pulmonaire des sclérodermies systémiques.